| 1430798-44-9

• 分子结构分类: 有机化合物 - 有机杂环化合物
• CAS: 1430798-44-9
• 化学式: C₁₈H₁₈N₂O₃
• 分子量: 310.353
• InChiKey: PEUYYRFAZFQMCX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.58
• 重原子数：
  23.0
• 可旋转键数：
  2.0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  75.09
• 氢给体数：
  2.0
• 氢受体数：
  4.0

反应信息

• 作为反应物：
  描述：

  在 salcomine 、 氧气 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 1-(cyclopropylmethyl)-4,6-dimethyl-9H-pyrido[3,2-g]quinoline-2,5,8,10-tetrone
  参考文献：
  名称：

  [EN] COMPOUNDS AND ANTI-TUMOR NQO1 SUBSTRATES
  [FR] COMPOSÉS ET SUBSTRATS ANTITUMORAUX NQO1

  摘要：

  化合物的化学式（I）可以选择性地对多种不同类型的癌细胞具有致命作用。这些化合物对于管理、治疗、控制或辅助治疗疾病非常有用，其中选择性的致命作用在化疗疗法中具有益处。

  公开号：

  WO2013056073A1
• 作为产物：
  描述：

  4,6-二氯-5-甲氧基-1,3-苯硼酸频哪醇酯 在 (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride 、 三溴化硼 、 potassium carbonate 、 三氟乙酸 、 2-二环己基磷-2,4,6-三异丙基联苯 作用下， 以 乙二醇二甲醚 、 二氯甲烷 、 水 、 异丙醇 为溶剂， 生成
  参考文献：
  名称：

  Efficient NQO1 Substrates are Potent and Selective Anticancer Agents

  摘要：

  A major goal of personalized medicine in oncology is the identification of drugs with predictable efficacy based on a specific trait of the cancer cell, as has been demonstrated with gleevec (presence of Bcr-Abl protein), herceptin (Her2 overexpression), and iressa (presence of a specific EGFR mutation). This is a challenging task, as it requires identifying a cellular component that is altered in cancer, but not normal cells, and discovering a compound that specifically interacts with it. The enzyme NQO1 is a potential target for personalized medicine, as it is overexpressed in many solid tumors. In normal cells NQO1 is inducibly expressed, and its major role is to detoxify quinones via bioreduction; however, certain quinones become more toxic after reduction by NQO1, and these compounds have potential as selective anticancer agents. Several quinones of this type have been reported, including mitomycin C, RH1, EO9, streptonigrin, beta-lapachone, and deoxynyboquinone (DNQ). However, no unified picture has emerged from these studies, and the key question regarding the relationship between NQO1 processing and anticancer activity remains unanswered. Here, we directly compare these quinones as substrates for NQO1 in vitro, and for their ability to kill cancer cells in culture in an NQO1-dependent manner. We show that DNQ is a superior NQO1 substrate, and we use computationally guided design to create DNQ analogues that have a spectrum of activities with NQO1. Assessment of these compounds definitively establishes a strong relationship between in vitro NQO1 processing and induction of cancer cell death and suggests these compounds are outstanding candidates for selective anticancer therapy.

  DOI：

  10.1021/cb4005832